Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

e to research and development. This compares to operating expenses of $19.6 million and research and development expenses of $17.6 million for the same nine month period last year. The Company reported a net loss for the nine months ended September 30, 2007 of $15.2 million compared to a net loss of $12.2 million for the same period last year.

TorreyPines merged with Axonyx Inc. on October 3, 2006. The Company's financial statements reflect the historical results of TorreyPines prior to the merger and that of the combined company following the merger, and do not include the historical results of Axonyx Inc. prior to the completion of the merger.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for tezampanel as a treatment for migraine, the potential timing, development and initiation of Phase III clinical trials of tezampanel, the potential for NGX267 to treat the symptoms of cognitive impairment associated with schizophrenia and the potential for NGX267 to treat dry mouth, or xerostomia. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPin
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... June 29, 2015 , ... ... Under the terms of the agreement, MediVet will acquire the rights to a ... MB-007 is currently in pre-clinical development as a potential next-generation treatment for various ...
(Date:6/29/2015)... , June 29, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors ... H. "Pete" Petit, has been awarded the Lifetime Achievement ... Southeast Program. The Entrepreneur Of The ...
(Date:6/29/2015)... SAN FRANCISCO, Calif. , June 29, 2015 /PRNewswire/ ... molecular diagnostics company pioneering the field of molecular cytology, ... Bay Area News Group,s prestigious Top Workplaces list for ... selects Top Workplace winners based solely on an annual ... are humbled and honored that the degree to which ...
(Date:6/26/2015)... CITY, Kan. , June 26, 2015 ... PETX ), a pet therapeutics company ... of innovative biopharmaceutical products for companion animals, ... field effectiveness study of capromorelin (AT-002), the ... dogs.  Capromorelin is a small molecule that ...
Breaking Biology Technology:MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5
... CAMBRIDGE, Mass., Jan. 5, 2011 Verenium Corporation (Nasdaq: ... and commercialization of high-performance industrial enzyme solutions, today announced ... Officer, will present at the upcoming Piper Jaffray Sixth ... scheduled to begin at 3:00 p.m. EST on Wednesday, ...
... and PUNE, India, Jan. 4, 2011 /PRNewswire-USNewswire/ ... unique and highly efficient Consolidated Bioprocessing (CBP) ... cellulosic ethanol, and Praj Industries Limited ( BSE: 522205 |  ... of innovative technology and engineering solutions for the ...
... Inc. (Nasdaq: ONXX ) today announced that it ... on Monday, January 10, 2011 at 1:00 p.m. Eastern Time ... access a live webcast of the presentation on our website ... is recommended that listeners log on 15 minutes early in ...
Cached Biology Technology:Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 2Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 3Qteros and Praj Industries Announce Broad Strategic Partnership to Accelerate Global Commercialization of Cellulosic Ethanol 2Qteros and Praj Industries Announce Broad Strategic Partnership to Accelerate Global Commercialization of Cellulosic Ethanol 3Qteros and Praj Industries Announce Broad Strategic Partnership to Accelerate Global Commercialization of Cellulosic Ethanol 4Qteros and Praj Industries Announce Broad Strategic Partnership to Accelerate Global Commercialization of Cellulosic Ethanol 5Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 2
(Date:6/23/2015)... 2015 Research and ... the "Body-Worn Temperature Sensors Market - Global ... 2014 - 2020" report to their offering. ... the global body-worn temperature sensors market. The global ... the basis of types, care setting, patient demographic, ...
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... "gatekeepers" that allow information and molecules to pass into ... study of these complex proteins has been restricted due ... researchers and the one-dimensional results these microscopes reveal. Now, ... three-dimensional microscope that will yield unparalleled study of membrane ...
... The latest episode in the American Chemical Society,s (ACS,) award-winning ... a new design for a highly sensitive device that can ... Based on a report by Jorge M. Seminario, ... Physical Chemistry C, the new podcast is available without charge ...
... RIVERSIDE, Calif. Chronic wounds affect an estimated 6.5 million ... foot blisters and other diabetic ulcers or sores account for ... United States today. Why does treating chronic wounds cost ... difficult? Manuela Martins-Green , a professor of ...
Cached Biology News:MU researchers develop advanced 3-dimensional 'force microscope' 2Researchers explain why some wound infections become chronic 2
... for use with dishes and cell culture ... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. Comp Dim: blade L 1.9 cm ...
... interferons are cytopathic effect inhibition assays, also ... The neutralization assay measures the antibody's ability ... cytokine. Sample types include; tissue culture supernatents; ... assays, one unit is defined as the ...
... The pTriEx™ vectors combine the proven features ... mammalian systems and provides all of the ... in one vector backbone. The pTriEx vectors ... various target genes in all three expression ...
... base medium for preparation of minimal and synthetic ... does not contain amino acids. Both bulk and ... contains reagents to prepare 500 ml of 10X ... 10X YNB for S. cerevisiae media. Store at ...
Biology Products: